MAM
Innocean India wins Narayana Health’s consolidated media mandate
MUMBAI: It’s go health on its mind, and now in its pocket. Innocean India, part of the global Innocean Network, has secured the consolidated media mandate for healthcare provider Narayana Health.
In an era where both online and offline media platforms dominate communication, ensuring timely and effective delivery of critical healthcare messages is paramount. With its expertise in strategic media planning and execution, Innocean aims to strengthen Narayana Health’s connection with its audience, fostering greater trust and accessibility.
By aligning Narayana Health’s commitment to care with Innocean’s innovative media strategies, this collaboration looks to reshape the way Indians engage with healthcare information, ensuring it is both impactful and life changing.
Narayana Health chief marketing officer Ashish Bajaj said, “We are delighted to partner with Innocean India for our media mandate. Their innovative approach to media planning and execution is exactly what we need to elevate our brand and expand our reach. We are confident that their expertise will play a pivotal role in achieving our objectives and making a significant impact on the healthcare landscape.”
Innocean won the mandate despite cut-throat manoeuvres from other agencies. Innocean India managing director Jaeho Yoo said: “Innocean India is honoured to partner with Narayana Health, a leader in the healthcare industry. We look forward to leveraging our expertise to help Narayana Health reach new heights in the healthcare industry. We will strive to introduce and collaborate on innovative media solutions through close cooperation with Innocean headquarters in Korea.”
Added Innocean chief operating officer Santosh Kumar: “Our partnership with Narayana Health is a pivotal step in Innocean’s 2.0 journey. In today’s evolving healthcare landscape, media plays a more critical role than ever in reaching and engaging patients. By leveraging the power of strategic media planning and execution, we aim to amplify Narayana Health’s commitment to providing quality healthcare with best-in-class facilities to millions across India. This partnership aligns perfectly with our vision of driving meaningful impact through innovative media solutions.”
Together, Innocean and Narayana Health aim to empower every individual with the critical information and knowledge they need for their well-being. Placing the consumer at the heart of their efforts, this partnership reflects a shared mission to prioritise health and safety. By combining their strengths, the duo hopes to take healthcare communication to a new high — making it more accessible, relatable, impactful, and deeply resonant with the needs of every individual.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
